aTyr Pharma Inactive 10-Q2013 Q1 Quarterly report

Filed: 2 May 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Bad

New words: absence, advance, alter, amendedASC, American, antitrust, assurance, binomial, cancer, Carlo, certainty, certified, CLIA, connection, consummated, consummation, contacting, correlation, coverage, crop, curtailment, customary, decide, Delaware, density, departure, description, divert, diverted, divesture, enactment, encouraging, exam, exemption, Exhibit, exploration, face, failure, Fisher, fluorescence, fluorescently, foregoing, found, free, GAAP, governmental, harm, hundred, ii, impression, inability, Israel, judge, lab, legislation, light, lose, lung, microscopy, minimum, Monte, morphology, move, novo, organismsde, organizational, pathogen, payout, pendency, percent, personnel, pioneer, predict, preliminary, President, prohibiting, prohibition, Promega, promoting, proposal, proposed, proxy, putative, quick, recommendation, recurrence, regenerative, regulatory, reinstated, Relief, respond, responded, restraining, restraint, retained, retiree, retroactively, reversed, satisfaction, set, shareholder, site, slightly, spun, stockholder, stratify, superior, supplier, suspended, Taxpayer, text, Thermo, uncertainty, urged, verification, waiver, web, Welfare, wholly

Removed: academic, accretion, actively, aggregation, ASCTopic, assumption, behavior, biodiscovery, biotechnology, charged, China, clinical, conform, consecutive, Conversely, convert, declared, dividend, efficient, entering, exercised, expectation, expertise, favorable, generated, holiday, impacted, implied, ineffective, input, Japan, June, leaving, modified, occurring, opposite, organization, performed, pharmaceutical, presentation, pursued, ratio, realization, recapture, reclassed, reclassification, relate, release, remain, representative, response, retire, retrospectively, simplify, SOLiDTM, structured, subsequently, taxed, tissue, TorrentTM, type, updating, wide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

aTyr Pharma similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, David F. Hoffmeister, Chief Financial Officer of Life Technologies Corporation (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	the Quarterly Report of Form 10-Q of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: May 2, 2013

/s/ David F. Hoffmeister

David F. Hoffmeister

Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Life Technologies and will be retained by Life Technologies and furnished to the Securities and Exchange Commission or its staff upon request.